companiesCompany
Veracyte (Decipher)
Veracyte makes the Decipher genomic classifier, the most-used gene-expression test in localised prostate cancer.
Decipher Prostate (22-gene GC) is NCCN level-1 evidence for prognostication in biopsy and post-prostatectomy settings, validated on NRG/RTOG randomised cohorts. Competes conceptually with ArteraAI's digital-pathology test.